JDRF T1D Fund

company

About

A venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities.

  • 11 - 50

Details

Founded date
Dec 1, 2016
Number Of Employee
11 - 50
Operating Status
Active
Investor Type
Venture Capital

The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Through partnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.

Investments

Number of Investments
Number of Lead Investments
5
1
JDRF T1D Fund has made 5 investments. Their most recent investment was on May 18, 2020, when SQZ Biotech raised $65M.
Date Company Name
Round Money Raised Industry Lead Investor
May 18, 2020 SQZ Biotech
Series D $65M Biotechnology
Mar 2, 2020 Immunocore
Series B $130M Biotechnology
Aug 8, 2018 SQZ Biotech
Series C $72M Biotechnology
Dec 5, 2017 SQZ Biotech
Series Unknown Biotechnology Yes
Jan 26, 2017 Provention Bio
Series A $28.40M Biotechnology